Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신진호 | - |
dc.contributor.author | 이해영 | - |
dc.contributor.author | 조은주 | - |
dc.contributor.author | 성기철 | - |
dc.contributor.author | 김주한 | - |
dc.contributor.author | 김대희 | - |
dc.contributor.author | 임상현 | - |
dc.contributor.author | 김광일 | - |
dc.contributor.author | 손일석 | - |
dc.contributor.author | 정욱진 | - |
dc.contributor.author | 김현창 | - |
dc.contributor.author | 유승기 | - |
dc.contributor.author | 편욱범 | - |
dc.contributor.author | 박성하 | - |
dc.date.accessioned | 2021-08-02T10:27:17Z | - |
dc.date.available | 2021-08-02T10:27:17Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 2635-6325 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/11528 | - |
dc.description.abstract | Abstract Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-AngiotensinAldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한고혈압학회 | - |
dc.title | Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic? | - |
dc.title.alternative | Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 신진호 | - |
dc.identifier.doi | 10.1186/s40885-020-00144-0 | - |
dc.identifier.bibliographicCitation | Clinical Hypertension, v.26, no.3, pp.26 - 30 | - |
dc.relation.isPartOf | Clinical Hypertension | - |
dc.citation.title | Clinical Hypertension | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 26 | - |
dc.citation.endPage | 30 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002606183 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Infection | - |
dc.subject.keywordAuthor | SARS | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | 2019 novel coronavirus | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordAuthor | Pandemic | - |
dc.subject.keywordAuthor | Antihypertensive drugs | - |
dc.subject.keywordAuthor | ACE inhibitor | - |
dc.subject.keywordAuthor | Angiotensin receptor blocker | - |
dc.subject.keywordAuthor | ACE2 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.